Status:
COMPLETED
MRI Perfusion on T1 and T2 Brain Lesion(s)
Lead Sponsor:
University Hospital, Lille
Conditions:
Lung Carcinoma Metastatic to the Brain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study therefore aims to assess current treatment recommended by scientific societies \[ 6-13 \] , brain MRI with injection of contrast for the diagnosis and monitoring of brain metastases . The r...
Detailed Description
Eligibility criteria: * Major Patients * Addressed MRI for initial assessment of brain metastases * At a suspicion of one or more brain metastases in the brain scanner routine screening * Follow for ...
Eligibility Criteria
Inclusion
- Major Patients
- Addressed to MRI for initial assessment of brain metastases
- At a suspicion of one or more brain metastases in the brain scanner routine screening
- Followed for lung cancer histologically documented in the Thoracic Oncology Service of Professor Lafitte (contact: Dr Cortot)
- To whom treatment with chemotherapy or targeted therapy (including anti-angiogenic) is considered
- Be socially insured-
Exclusion
- Absolute contraindication to MRI (pacemaker, implantable pacemaker, metallic foreign body intraorbital)
- Patients minors under guardianship / curatorship
- Patients with impaired judgment skills or unable to receive information
- Pregnant Women
- Patients for which lesions are not compatible with lung metastases
- Patients with brain metastases or already known and explored MRI
- Patients for whom treatment by surgical excision of brain metastases is considered
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT02250755
Start Date
June 1 2013
End Date
November 1 2015
Last Update
November 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Salengro CHRU de Lille
Lille, France, 59037